Weight, waist, blood pressure, fasting glucose, lipids and AIMS each get a schedule and a trigger in an MN663 Unit 4 protocol built around a composite man starting olanzapine. Searches like "mn 663 unit 4 assignment example", "mn663 unit 4 sample" and "mn663 unit 4 example" land here.
Monitoring Protocol for Olanzapine in a 44-Year-Old With Schizophrenia: What to Measure, When, and What Sends the Plan Back
[Student Name]
Purdue University Global
MN663: PMHNP Diagnosis and Management Across the Lifespan I
Unit 4 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. Baseline values are illustrative; nothing here is a prescribing instruction.
Sources and Baseline
Schedule sources: the consensus statement on antipsychotic drugs, obesity and diabetes from the American Diabetes Association, American Psychiatric Association and others (American Diabetes Association et al., 2004), and the American Psychiatric Association's schizophrenia guideline (Keepers et al., 2020). Where this protocol goes further than those sources, it says so.
His baseline values: weight 88 kg, body mass index 28.7, waist circumference 102 cm, blood pressure 128/82, fasting glucose 98 mg/dL, fasting lipid panel with triglycerides 162 mg/dL and HDL cholesterol 38 mg/dL. Abnormal Involuntary Movement Scale (AIMS) score 0. He smokes a pack a day, which also matters because smoking lowers olanzapine levels.
Metabolic Band
Weight: baseline, weeks 4, 8 and 12, then every three months. Waist circumference: baseline and yearly. Blood pressure: baseline, week 12 and yearly. Fasting glucose or hemoglobin A1c: baseline, week 12 and yearly. Fasting lipid panel: baseline and week 12, then yearly in this protocol, more often than the consensus statement's five-year interval, because his baseline triglycerides and HDL are already abnormal.
The first twelve weeks are dense because much of the weight gain with olanzapine appears early, and a change caught at week 4 or 8 can still be addressed before it becomes established. Olanzapine is among the antipsychotics associated with the largest average weight gain in pooled analyses (Allison et al., 1999).
Movement Band
AIMS at baseline, then every 12 months, or every 6 months if he develops risk factors for tardive dyskinesia, following the guideline's schedule by risk (Keepers et al., 2020). Questions about stiffness, tremor and restlessness at each visit.
Acute Tolerability Band
At every visit: sedation, including whether he feels alert enough to operate a forklift safely; dizziness on standing; constipation; rash. This protocol adds the forklift question, which the sources do not specify, because sedation at work is a safety risk for him and his coworkers.
Trigger Rules
A gain reaching 5 percent above his baseline weight, about 4.4 kg: review diet and activity with him, refer to a nutrition program, and discuss whether to switch to an antipsychotic with less metabolic risk, weighing that against his current symptom control.
Fasting glucose 100 to 125 mg/dL or A1c 5.7 to 6.4 percent: confirm on repeat testing, notify his primary care provider and intensify lifestyle support. Fasting glucose 126 mg/dL or higher, or A1c 6.5 percent or higher, confirmed: diagnose diabetes jointly with primary care, start diabetes management and review the antipsychotic.
Triglycerides 200 mg/dL or higher, or worsening HDL: notify primary care for lipid management and review the antipsychotic.
Blood pressure 140/90 or higher on two visits: notify primary care.
Any increase in AIMS score, or new abnormal movements: repeat the examination within a month, review the antipsychotic and consider referral.
Sedation that affects his safety at work: review the dose and timing the same week, and advise him not to operate the forklift until reviewed.
Smoking and Olanzapine Levels
Smoking induces the liver enzyme CYP1A2, which breaks down olanzapine, so smokers often need higher doses to reach the same blood level. If he cuts down or quits, which the clinic will encourage, his olanzapine level can rise over the following weeks and bring more sedation and weight gain. The protocol therefore adds a trigger: any change in smoking, reported at a visit, prompts closer checks of sedation and weight over the next month and a review of the dose.
Talking With Him About the Protocol
The schedule is explained to him at the first visit in plain terms: the medicine is helping, it can also cause weight gain and raise blood sugar, and the checks are how the clinic will catch those early. He is given a one-page calendar showing when each check is due and what it is for. He asked whether he could weigh himself at home; the protocol accepts home weights between visits if he uses the same scale and records them, and clinic weights remain the official measure. He also asked what would happen if his weight went up, and he was told honestly that the options include diet and activity support, a switch to a different antipsychotic or medication to help with weight, and that he will be part of that decision.
Who Receives a Result and How Fast
Abnormal laboratory results go to the prescribing nurse practitioner within two business days and to his primary care provider the same week. A fasting glucose of 200 mg/dL or higher, or symptoms of diabetes such as heavy thirst and urination, prompts a call to him the same day. Movement findings are reviewed by the prescriber at the visit.
Rationale
The protocol exists because of a real tension: olanzapine is working for his symptoms, and stopping it would risk relapse, but it carries metabolic risks that could shorten his life. Monitoring on a fixed schedule, with clear triggers, allows the benefit to continue while catching harm early enough to act.
References
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999). Antipsychotic-induced weight gain: A comprehensive research synthesis. American Journal of Psychiatry, 156(11), 1686-1696. https://doi.org/10.1176/ajp.156.11.1686
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601. https://doi.org/10.2337/diacare.27.2.596
Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A., & Hong, S.-H. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 177(9), 868-872. https://doi.org/10.1176/appi.ajp.2020.177901
How this MN663 Unit 4 example is structured
Measures are grouped by the harm they detect rather than by the order a clinic would draw them, so metabolic, movement and acute tolerability each form a band. Every row carries four entries: what is measured, when, the result that counts as a change, and what happens next. The protocol names its sources in the header and follows them instead of improvising a calendar, flagging the places it goes further, such as asking about sedation at each visit. Baseline values are bracketed so the thresholds can be read against his own numbers: weight 88 kg, fasting glucose 98 mg/dL, waist 102 cm. A rationale paragraph explains why the first twelve weeks are dense, since much of the early weight gain on this drug arrives then. A closing section lists who receives an abnormal result and how quickly.
Get an MN663 Unit 4 example written to your instructions
Tell us which agent your MN663 Unit 4 prompt monitors and whether it names a guideline or leaves the source open, then attach the case and rubric. Laid out as a schedule grid with a threshold and an action beside every row, the first protocol is free and back within 24-48h. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN663 Unit 4 questions, answered
Which guideline should an antipsychotic monitoring protocol cite?
The 2004 consensus statement from the American Diabetes Association and the American Psychiatric Association, with others, remains the most widely cited metabolic schedule, and the APA's 2020 schizophrenia guideline covers movement assessment. If your course names a different source, use it and say so. Whatever the source, reproduce its intervals exactly and label any check the protocol adds.
Should the protocol include ECG monitoring?
That depends on the drug and the person. For olanzapine in an adult without cardiac history, routine ECGs are not usually part of the schedule, while agents with more QT concern, or patients with heart disease or interacting medications, change the answer. State the reasoning either way, because an ECG row with no stated purpose reads as habit.
How detailed should the trigger actions be?
Clear enough that the next step is unambiguous: repeat the test, refer to primary care, discuss switching, or contact the prescriber the same day. The sample names the action without writing a new regimen, since that decision belongs to the prescriber. A trigger that says only monitor closely gives the reader nothing to do.